News AnalysisRegulatory News FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claimsClinical benefit will not be considered for approval, FDA says September 25, 2026Vol.52 No.35By Jacquelyn Cobb and Sara Willa Ernst
News Analysis Trump weighs—and abandons—an executive order that would give OMB veto power over NIH grants September 25, 2026Vol.52 No.35By Paul Goldberg
News Analysis Prediction markets now allow betting on clinical trial results, FDA decisionsIt’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake July 31, 2026Vol.52 No.30By Sara Willa Ernst
News Analysis A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m. July 10, 2026Vol.52 No.27By Jacquelyn Cobb
News Analysis FDA clears a way for dramatic reduction in animal toxicology studies in cancer June 18, 2026Vol.52 No.24By Claire Marie Porter
News Analysis HHS presents new protein-forward dietary guidelines, turning the food pyramid upside downThe Kennedy guidelines are mum on cancer risks associated with red meat and alcohol April 03, 2026Vol.52 No.13By Claire Marie Porter
News Analysis GRAIL presses on with Galleri test despite missed primary endpoint in pivotal studyWhere GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis March 06, 2026Vol.52 No.09By Jacquelyn Cobb and Sara Willa Ernst
News Analysis NIH Director Bhattacharya named acting CDC director in latest public health shakeupThe temporary appointment concentrates vast authority in the hands of one person February 20, 2026Vol.52 No.07By Claire Marie Porter
News Analysis ACS report trumpets 70% five-year survival for all cancers amid uncertain funding outlook January 16, 2026Vol.52 No.02By Jacquelyn Cobb and Paul Goldberg
NCINews Analysis Cancer centers adapt to life without site visits as NIH changes CCSG review October 31, 2025Vol.51 No.40By Paul Goldberg
